Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.

Learn More
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

view all Clinical Trials

Overview

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).

The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.

Clinical Trial Information

Protocol

TIRB# 31532

Phase

2

Condition(s)

Idiopathic Pulmonary Fibrosis (IPF), Interstitial Lung Disease (ILD), Pulmonary Fibrosis (Including IPF)

Investigator

Gerard Criner, MD

Coordinator

Kriti Mittal

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)